Effects of Different Therapeutic Schedules on Patients with COVID-19: A Prospective Case–Control Study in China

Table 2

Laboratory test results of SARS-CoV-2 patients.

Variables	Total patients ()	WM treatment group ()	TCM-WM treatment group ()
Blood routine
White blood cell count (×10^9/L)	4.9 (4.0-6.7)	5.0 (4.1-6.4)	4.9 (4.0-6.3)	0.412
Neutrophil count (×10^9/L)	3.0 (2.3-3.8)	3.1 (2.5-3.9)	3.0 (2.3-4.1)	0.512
Lymphocyte count (×10^9/L) 10^9/L)	1.2 (0.8-1.7)	1.3 (0.9-1.9)	1.2 (0.8-1.8)	0.406
Monocyte count (×10^9/L)	0.5 (0.3-0.7)	0.5 (0.3-0.8)	0.4 (0.3-0.5)	0.296
Platelet count (×10^9/L)				0.421
Hemoglobin (g/L)				0.362
Blood biochemistry
Alanine aminotransferase (U/L)	21 (14-36)	21 (15-39)	20 (11-34)	0.698
Albumin (g/L)	41.5 (38.3-44.7)	42.1 (39.1-45.2)	40.2 (38.1-42.8)	0.137
Blood urea nitrogen (mmol/L)	4.2 (3.0-5.2)	4.2 (3.2-5.2)	4.3 (2.8-5.0)	0.286
Serum creatinine (μmol/L)	59.7 (49.5-74.2)	58.6 (48.8-72.0)	61.0 (51.0-72.0)	0.136
Lactate dehydrogenase (U/L)	191 (155-278)	182 (149-265)	199 (154-310)	0.105
Glucose (mmol/L)	5.9 (4.8-7.0)	5.7 (4.7-6.8)	6.3 (5.2-8.1)	0.085
Creatine kinase (U/L)	67 (49-125)	69 (54-111)	63 (47-90)	0.347
Creatine kinase–MB (U/L)	11 (8-17)	12 (7-18)	10 (8-13)	0.255
PaO2	99 (84-136)	94 (82-113)	108 (94-147)	0.117
PaO2/FiO2	473 (365-607)	466 (344-592)	495 (393-616)	0.108
Coagulation function
Activated partial thromboplastin time (s)				0.093
Prothrombin time (s)	12.1 (11.6-13.2)	12.2 (11.7-13.4)	11.8 (11.5-12.5)	0.104
D-dimer(μg/L)	0.3 (0.2-0.8)	0.3 (0.2-0.6)	0.2 (0.1-0.4)	0.136
Infection-related biomarkers
C-reactive protein	7.8 (3.2-19.9)	7.7 (3.6-19.8)	8.0 (4.0-23.5)	0.079
Procalcitonin	0.6 (0.3-1.0)	0.9 (0.3-1.2)	0.3 (0.2-0.5)	0.017
Erythrocyte sedimentation rate	14.5 (8.3-26.9)	13.9 (8.4-22.0)	15.5 (8.0-37.8)	0.062
Coinfection
Other viruses	1 (0.56%)	1 (0.80%)	0 (0.00%)	0.106
Bacteria	1 (0.56%)	1 (0.80%)	0 (0.00%)	0.106
Fungi	0 (0.00%)	0 (0.00%)	0 (0.00%)	1.000